Progression of noncalcified and calcified coronary plaque by CT angiography in SLE

Khan, Aisha; Arbab‐Zadeh, Armin; Kiani, Adnan N.; Magder, Laurence S.; Petri, Michelle

doi:10.1007/s00296-016-3615-z

Cited by 23 publications

(20 citation statements)

References 35 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Supporting the face validity property, PGA was defined “gold-standard” in 11 studies (2, 10-11, 21, 32, 49, 67, 76, 78, 84, 88) and in 32 it was used as the reference to which other activity scores were compared, such as the SLEDAI (4, 10, 13, 25, 27-28, 31, 33, 35-36, 41, 46-47, 50-51, 53, 62, 65, 68, 72-73, 76, 81, 96-99), BILAG (4, 27, 35-36, 46, 65, 72-73, 81, 98), SLAM (4, 72, 76, 99), LAI (68, 88), patient global assessment (ptGA) (81, 83-84) and ECLAM (35). However, it was used as a single outcome measure only in two studies (49, 100) whilst in the majority the PGA was scored together with another instrument (typically the SLEDAI) (2, 9, 11-12, 21, 24, 30, 32, 34, 37-40, 44-45, 48-49, 55, 58-59, 61, 63-64, 66-67, 74-75, 80, 82, 86, 89-95, 103).…”

Section: Resultsmentioning

confidence: 99%

“…In one open-label study (43) the decrease in PGA score was considered the primary endpoint. In 32 studies, disease activity measured by PGA was compared to changes in laboratory markers, with the aim to correlate clinical and serological features (9, 21, 30, 32, 34, 37-39, 44-45, 48-49, 55, 58-61, 63-64, 66-67, 69, 71, 74-75, 82, 86, 89, 91-94).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Use of Physician Global Assessment (PGA) in Systemic lupus erythematosus: a systematic review of its psychometric properties

Chessa

Piga

Floris

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Physician Global Assessment (PGA) is a visual analogue score (VAS) that reflects the clinician's judgment of overall Systemic Lupus Erythematosus (SLE) disease activity. The aim of this systematic literature review (SLR) is to describe and analyse the psychometric properties of PGA. Methods: This SLR was conducted by two independent reviewers in accordance with the PRISMA statement. All articles published until the 1st of July 2019 in Pubmed were screened with no limitation about years of publication, language or patients' age. Psychometric properties data were analysed according to the OMERACT Filter methodology version 2.1. Results: The literature search identified 91 studies. Face validity was reported in all the articles retrieved, in which the PGA was used alone or as part of composite indices (SRI, SFI, LLDAS, DORIS remission criteria). Content validity was reported in 89 studies. Construct validity was demonstrated by a good correlation between the PGA with the SLEDAI (12 studies), SLAM (4 studies), LAI, BILAG and ECLAM (2 studies each). Criterion validity was assessed exploring the PGA correlation with quality of life measurements, biomarkers levels and treatment changes in 28 studies, while no study has evaluated correlation with damage. A good responsiveness for PGA was shown in 8 studies. A high variability in scales was found, causing a wide range of reliability (ICC=0.67-0.98). Conclusion: PGA is a valid, responsive and feasible instrument, while its reliability was impacted by the scale adopted, suggesting the major need for a standardization of its scoring.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Use of Physician Global Assessment (PGA) in Systemic lupus erythematosus: a systematic review of its psychometric properties

Chessa

Piga

Floris

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…A total of 891 patients participated in the study, and 420,142 clinical cases were analyzed from hospital records. [11][12][13][14][15][16][17][18][19][20]. Almost all studies (90% studies) were conducted in the United States of America [11][12][13][14][15][16][17]19,20].…”

Section: Literature Searchmentioning

confidence: 99%

“…Among the included studies, six studies were prospective cohort [11][12][13][14]19,20]. Two studies were longitudinal [17,19]. One study was a retrospective cohort [15].…”

Section: Literature Searchmentioning

confidence: 99%

See 1 more Smart Citation

Elucidating the Intriguing Association Between Systemic Lupus Erythematosus and Cardiovascular Disease

Malik¹,

Gor²,

Siddiqui³

et al. 2021

Cureus

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) patients have demonstrated a higher risk of developing cardiovascular disease (CVD), resulting in it being one of the leading causes of death in SLE patients. SLE itself acts as a sole risk factor influencing the prevalence and progression of CVD. However, conventional risk factors, such as age, hypertension, smoking, and obesity, play a crucial role as well. Therefore, this systematic review attempts to unravel the association of CVD in SLE patients while evaluating the role of conventional risk factors.Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed to search the PubMed database starting from March 2021 systematically. Original studies that evaluated the prevalence and progression of CVD in SLE patients were extracted by two reviewers independently. Quality in Prognostic Studies (QUIPS) tool was used to assess the risk of bias. Most studies have a moderate to low risk of bias. Among 3,653 studies identified by our search, 10 studies were included in the review. Strong epidemiologic evidence of SLE patients having an increased relative risk of CVD compared to controls was found. Traditional CVD risk factors, such as age, hypertension, obesity, and smoking, influence the prevalence of CVD among SLE patients. Several SLE-specific factors such disease activity, duration, and certain medications also acted as influencing factors. However, the relative risk of CVD was still higher in SLE patients after adjustment of certain risk factors. One study found that the odds of having a Coronary Artery Calcification (CAC) score greater than zero in women with SLE aged less than or equal to 45 years was 12.6 times higher than women in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort (95% CI 5.2 to 30.7) (participants of CARDIA cohort acted as control). This finding was made after age, hypertension, total cholesterol levels, and aspirin use were adjusted, and the study was restricted to women.Although conventional risk factors increase CVD prevalence, SLE itself also dramatically increases the prevalence of CVD. Therefore, we recommend that SLE should be treated as a "CVD risk equivalent." SLE patients should be managed more extensively with greater emphasis given to cardiac health for better clinical outcomes.

show abstract

Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus

et al. 2019

View full text Add to dashboard Cite

Progression of noncalcified and calcified coronary plaque by CT angiography in SLE

Cited by 23 publications

References 35 publications

Use of Physician Global Assessment (PGA) in Systemic lupus erythematosus: a systematic review of its psychometric properties

Use of Physician Global Assessment (PGA) in Systemic lupus erythematosus: a systematic review of its psychometric properties

Elucidating the Intriguing Association Between Systemic Lupus Erythematosus and Cardiovascular Disease

Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus

Contact Info

Product

Resources

About